Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat long-term extension in PAH (PATENT-2)
NCT00863681Phase 3Completed
- Sponsor
- Bayer
- Start
- Mar 2009
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 27
01
Overview
Phase 3, open-label, single-arm trial of riociguat in pulmonary arterial hypertension (PAH), sponsored by Bayer. Primary endpoints: Treatment-emergent Adverse Events and Number of Participant With Death. Started Mar 2009; status: completed.
02
Drugs
riociguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00863681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00863681.